People · Operator
Named in public records as an officer, director or promoter · active 2009–2023 · Biotechnology, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Magnolia Neurosciences Corp | — | Biotechnology | Series B | $26.4M | $725.3M | 2018 |
| Rodeo Therapeutics Corp | — | Biotechnology | Series A | $14.3M | $323.6M | 2018 |
| Automera US Inc. | — | Biotechnology | Series A | $12.2M | $95.2M | 2023 |
| KayoThera, Inc. | — | Other | Series A | $11.2M | $95.3M | 2022 |
| Trubion Pharmaceuticals, Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
Kendall Mohler at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Kendall Mohler on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thong Le | 4 | 12 |
| Ian Howes | 4 | 5 |
| Suzanne Rettenmier | 3 | 3 |
| Asish Xavier | 2 | 18 |
| Steve Gillis | 2 | 13 |
| David Schubert | 2 | 6 |
| Steven Gillis | 1 | 23 |
| Peter Thompson | 1 | 16 |
| Patrick Heron | 1 | 11 |
| Joel Marcus | 1 | 9 |
| Lindsay Rayle | 1 | 7 |
| Sean Cassidy | 1 | 7 |
| David Schnell | 1 | 7 |
| James Sullivan | 1 | 7 |
| Joel Johnston Marcus | 1 | 5 |
| M. Johnston Erwin | 1 | 5 |
| Michael Baran | 1 | 4 |
| Mitchell Hymowitz | 1 | 4 |
| Margarita Chavez | 1 | 4 |
| Barbara Johnston Dalton | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.